CD8A and neoplasm: It was found that the combination of CTLA-4 blockade and 4-1BB co-stimulation could increase tumor infiltrating lymphocytes, such as CD4+ and CD8+ T cells, contributing to further tumor eradication and, eventually, survival improvement (51–53).